-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Enibarcimab
| Category | SARS-CoV |
| CAS | 2305638-98-4 |
| Description | Enibarcimab is a humanized monoclonal antibody that has been investigated as a medication for the treatment of acute heart failure and COVID-19. |
Product Information
| Synonyms | HAM 8101; HAM-8101; HAM8101 |
| Molecular Weight | 428.6 |
| Molecular Formula | C29H36N2O |
| Canonical SMILES | C1CN(CCC1NC(=O)C23CC4CC(C2)CC(C4)(C3)C5=CC=CC=C5)CC6=CC=CC=C6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
